Phase II study of interferon-gamma and interleukin-2: tachyphylaxis of toxicity to the liver during increasing immune enhancement.
Baars
J W
JW
Wagstaff
J
J
Van Groeningen
C J
CJ
Vermorken
J B
JB
Bijvank
E M
EM
Pinedo
H M
HM
Nauta
J J
JJ
D002292:Carcinoma, Renal Cell / Q000628:therapy; D004334:Drug Administration Schedule; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000008:administration & dosage / Q000009:adverse effects*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000628:therapy; D008099:Liver / Q000187:drug effects*; D008545:Melanoma / Q000628:therapy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects
D007376:Interleukin-2; D011994:Recombinant Proteins; D007371:Interferon-gamma